Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension
Lorundrostat was associated with greater reductions in 24-hour average blood pressure than placebo in participants with uncontrolled and treatment-resistant hypertension. (Funded by Mineralys Therapeutics; Advance-HTN ClinicalTrials.gov number, NCT05769608.).
Authors
- M. J. Wilkinson (ORCID: https://orcid.org/0000-0002-9881-6993)
- James Matthew Luther (ORCID: https://orcid.org/0000-0001-7225-2897)
- Carrie Melgaard
- David Rodman
- Matthew R. Weir (ORCID: https://orcid.org/0000-0001-8820-5702)
- Steven E. Nissen (ORCID: https://orcid.org/0000-0002-7231-6464)
- John M. Flack (ORCID: https://orcid.org/0000-0003-2584-5598)
- Ashish Sarraju (ORCID: https://orcid.org/0000-0003-1649-2110)
- Branko Kopjar (ORCID: https://orcid.org/0000-0001-6789-5417)
- Elizabeth Ofili (ORCID: https://orcid.org/0000-0003-4663-1767)
- Luke J. Laffin (ORCID: https://orcid.org/0000-0002-3262-792X)
- Reena Mehra (ORCID: https://orcid.org/0000-0002-6222-2675)
- Kathy Wolski
- Debbie L. Cohen
- Jessica Ibbitson
- Shivani Bhikam
Institutions
- University of Maryland, Baltimore (US)
- Cleveland Clinic (US)
- Southern Illinois University School of Medicine (US)
- University of Washington (US)
- University of California San Diego (US)
- Center for Clinical Research (United States) (US)
- Morehouse School of Medicine (US)
- University of Pennsylvania (US)
- Vanderbilt University Medical Center (US)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2025-04-23
- DOI
- https://doi.org/10.1056/nejmoa2501440
- Citations
- 70
- Primary Topic
- Hormonal Regulation and Hypertension
- Type
- article
- Field-Weighted Citation Impact
- 90.65